Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Ningbo Menovo Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:603538'
s EV-to-FCF Range Over the Past 10 Years
Min: -3204.97 Med: -25.5 Max: 777.73
Current: 328.54
During the past 13 years, the highest EV-to-FCF of Ningbo Menovo Pharmaceutical Co was 777.73. The lowest was -3204.97. And the median was -25.50.
SHSE:603538's EV-to-FCF is ranked worse than 95.61% of 570
companies
in the Drug Manufacturers industry
Industry Median: 20.645
vs SHSE:603538: 328.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ningbo Menovo Pharmaceutical Co (SHSE:603538) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ningbo Menovo Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Ningbo Menovo Pharmaceutical Co's share price for today is ¥24.72.
Ningbo Menovo Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.343.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ningbo Menovo Pharmaceutical Co EV-to-FCF Related Terms
Ningbo Menovo Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ningbo Menovo Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ningbo Menovo Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ningbo Menovo Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ningbo Menovo Pharmaceutical Co's EV-to-FCF falls into.
Ningbo Menovo Pharmaceutical Co's current Enterprise Value is ¥9,185 Mil.
Ningbo Menovo Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a EV-to-FCF of 328.54 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. According to the industry distribution chart, Ningbo Menovo Pharmaceutical Co ranks #545 out of 570 companies in the Drug Manufacturers industry, placing it in the top 95.6%.
Is Ningbo Menovo Pharmaceutical Co's EV-to-FCF too high?
Ningbo Menovo Pharmaceutical Co's current EV-to-FCF is 328.54. The Drug Manufacturers industry median EV-to-FCF is 20.65. Ningbo Menovo Pharmaceutical Co's value of 328.54 is 1491.4% above this industry median. Based on the distribution chart, Ningbo Menovo Pharmaceutical Co ranks #545 out of 570 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ningbo Menovo Pharmaceutical Co ranks #545 out of 570 companies for EV-to-FCF. This places Ningbo Menovo Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 20.65. Ningbo Menovo Pharmaceutical Co's value of 328.54 is 1491.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.65, based on 570 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ningbo Menovo Pharmaceutical Co's current EV-to-FCF of 328.54 is 1491.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningbo Menovo Pharmaceutical Co's current EV-to-FCF is 328.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥16.42, compared to a current price of ¥24.72 — trading 50.5% above its estimated fair value. The current EV-to-FCF is 328.54 and 1491.4% above the Drug Manufacturers industry median of 20.65. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current EV-to-FCF is 328.54 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥24.72 is trading 50.5% above its estimated GF Value™ of ¥16.42.
GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:603538:
EV-to-FCF: 328.54
GF Value™: ¥16.42 vs. price of ¥24.72 (50.5% above fair value)
Industry Position: 1491.4% above the Drug Manufacturers median (#545 of 570)
No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
68GF Score
Get the complete analysis for SHSE:603538
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603538 has been successfully added to your 
